US20040259922A1 - Epothilone derivatives, a process for their production thereof and their use - Google Patents
Epothilone derivatives, a process for their production thereof and their use Download PDFInfo
- Publication number
- US20040259922A1 US20040259922A1 US10/780,181 US78018104A US2004259922A1 US 20040259922 A1 US20040259922 A1 US 20040259922A1 US 78018104 A US78018104 A US 78018104A US 2004259922 A1 US2004259922 A1 US 2004259922A1
- Authority
- US
- United States
- Prior art keywords
- compound
- formula
- group
- alkyl
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*][C@@]12CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=C[2*])C[C@@H]1O2.[1*][C@@]12CCC[C@H](C)[C@H](OP)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=CB(O)O)C[C@@H]1O2.[1*][C@@]12CCC[C@H](C)[C@H](OP)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=CC)C[C@@H]1O2.[1*][C@@]12CCC[C@H](C)[C@H](OP)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=C[2*])C[C@@H]1O2.[1*][C@@]12CCC[C@H](C)[C@H](OP)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=O)C[C@@H]1O2 Chemical compound [1*][C@@]12CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=C[2*])C[C@@H]1O2.[1*][C@@]12CCC[C@H](C)[C@H](OP)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=CB(O)O)C[C@@H]1O2.[1*][C@@]12CCC[C@H](C)[C@H](OP)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=CC)C[C@@H]1O2.[1*][C@@]12CCC[C@H](C)[C@H](OP)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=C[2*])C[C@@H]1O2.[1*][C@@]12CCC[C@H](C)[C@H](OP)[C@@H](C)C(=O)C(C)(C)[Y]CC(=O)O[C@]([H])(C(C)=O)C[C@@H]1O2 0.000 description 7
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates generally to epothilon derivatives, to processes for their production and to their use in the manufacture of medicaments and plant protection agents.
- the invention relates especially to epothilon derivatives of the general formulae 2 to 6 shown below and to their use as medicaments and plant protection agents.
- R 1 a H atom or a C 1 - to C 8 -alkyl group, preferably a C 1 - to C 6 -alkyl group, especially preferably a C 1 - to C 4 -alkyl group, especially a methyl, ethyl, propyl or butyl group,
- R 2 a monocyclic aromatic group, such as a 5- or 6-membered aromatic group (such as a phenyl ring) or a vinyl group, each of which may be substituted in the ortho- and/or meta- and/or para-position(s) by one, two, three, four or five, especially one or two, halogen atoms and/or OR 4 and/or NR 5 R 6 groups and/or alkyl and/or alkenyl and/or alkynyl groups, wherein R 4 , R 5 and R 6 each independently of the others have the same meanings as R 1 , but are independent of R 1 , or
- R 2 a monocyclic 5- or 6-membered heteroaromatic group which may have one or more, especially one or two, O and/or N and/or S atoms in the ring and/or may have OR 4 and/or NR 5 R 6 groups and/or alkyl and/or alkenyl and/or alkynyl groups as substituents, wherein R 4 , R 5 and R 6 are as defined above.
- R 2 there are especially preferred C 1 -C 6 -alkyl or C 2 -C 6 -alkenyl and -alkynyl groups, especially C 1 -C 4 -alkyl or C 2 -C 4 -alkenyl and -alkynyl groups.
- alkyl groups there are especially preferred methyl, ethyl, propyl and butyl groups and as heteroaromatic groups 6-membered heteroaromatic groups,
- Hal a halogen atom, such as Br or I
- X-Y a group of the formula —CH 2 CH—OP or —CH ⁇ CH—
- P a protecting group, such as TMS.
- the compounds according to the invention may be produced as follows:
- Compounds of the formula (2) may be produced by reacting compounds of the formula (1)
- Compounds of the formula (3) are obtainable by reacting a compound of the formula (2) with a compound of the formula HC[B(OR) 2 ] 3 , such as tris(ethylenedioxyboryl)methane; R may be an alkyl or alkenyl group as defined above.
- a strong base such as a C 1 -C 4 -alkyl-Li compound (such as butyllithium) or a di-C 1 -C 4 -alkylamine-Li compound (such as a dimethylamine-lithium compound).
- the reaction is generally carried out at low temperatures, such as, for example, at temperatures of less than ⁇ 30° C., preferably at temperatures of less than ⁇ 50° C., especially preferably at temperatures of at least ⁇ 78° C. Further reaction conditions may be found in D. Schummer, G. Höfle in Tetrahedron 1995, 51, 11219.
- a compound of the formula (2) is reacted with tris(ethylenedioxyboryl)methane and butyllithium at ⁇ 78° C. to form a compound of the formula (3).
- a compound of the formula (4) may be produced from a compound of the formula (3) by reaction with N-iodo- or N-bromo-succinimide, optionally in a polar solvent, such as acetonitrile. Further reaction conditions may be found in the following literature reference: N. A. Petasis, I. A. Zavialor, Tetrahedron Lett. 1996, 37, 567.
- a compound of the formula (3) may be reacted within the framework of a Suzuki coupling with a compound of the formula R 2 -Z, wherein R 2 has the meanings given above and Z may be a halogen atom or a group of the formula —OSO 2 CF 3 , —CH ⁇ CHI, —CH ⁇ CHOSO 2 CF 3 .
- the group R 2 -Z may especially have the following structures:
- a 1 represents O, S, N or C atoms and the substituents O—, N— and C— correspond to the above-described groups OR 4 , NR 5 R 6 and alkyl, alkenyl and/or alkynyl groups.
- substituents “C” are C 1 -C 6 -alkyl or C 2 -C 6 -alkenyl and/or -alkynyl groups, especially C 1 -C 4 -alkyl or C 2 -C 4 -alkenyl and/or -alkynyl groups.
- alkyl groups there are especially preferred methyl, ethyl, propyl and butyl groups.
- a compound of the formula (5) may be produced by reacting a compound of the formula (4) by means of a Stille coupling with R 2 —SnR 3 3 , wherein R 2 is as defined above and R 3 is a C 1 - to C 6 -alkyl group, preferably a C 1 - to C 4 -alkyl group and especially preferably a methyl, ethyl, propyl or butyl group.
- R 2 —SnR 3 3 may have one of the following structures:
- a compound of the formula (6) may be produced by removing the protecting group from the compound of the formula (5), for example with a weak acid, such as citric acid, or compounds such as TBAF, pyridine ⁇ HF.
- a weak acid such as citric acid
- compounds such as TBAF, pyridine ⁇ HF.
- an alcohol such as methanol, may be used as solvent, the temperature preferably being adjusted to values of, for example, from 40 to 60° C., preferably about 50° C.
- the compound of the formula (6) may be produced by the above-described steps (epothilon A or B ⁇ (2) ⁇ (3) ⁇ (4) ⁇ (5) ⁇ (6) or epothilon A or B ⁇ (2) ⁇ (3) ⁇ (5) ⁇ (6)).
- medicaments that contain at least one of the compounds (2), (3), (4), (5) or (6) and optionally customary carriers, diluents and adjuvants.
- Such compounds may especially be used also as cytostatic agents and for plant protection in agriculture and/or forestry and/or in horticulture, the compounds optionally being used together with one or more customary carriers, adjuvants and/or diluents.
- N-iodosuccinimide (6.0 mg, 27 ⁇ mol) was added under inert gas and with the exclusion of light to a solution of alkenylboronic acid 3 (12 mg, 21 ⁇ mol; E/Z 9:1) in CH 3 CN (150 ⁇ l) and stirred for 3 hours. After concentration, the residue was purified by means of preparative thin-layer chromatography (SiO 2 , CH 2 Cl 2 /MeOH 95:5). 9 mg (66%) of the iodovinyl derivative 4 were isolated in the form of an E/Z-isomeric mixture (9:1).
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The present invention relates to epothilon derivatives, processes for their production and their use in the manufacture of medicaments and plant protection agents.
Description
- The present invention relates generally to epothilon derivatives, to processes for their production and to their use in the manufacture of medicaments and plant protection agents. The invention relates especially to epothilon derivatives of the general formulae 2 to 6 shown below and to their use as medicaments and plant protection agents.
- In the above formulae:
- R1=a H atom or a C1- to C8-alkyl group, preferably a C1- to C6-alkyl group, especially preferably a C1- to C4-alkyl group, especially a methyl, ethyl, propyl or butyl group,
- R2=a monocyclic aromatic group, such as a 5- or 6-membered aromatic group (such as a phenyl ring) or a vinyl group, each of which may be substituted in the ortho- and/or meta- and/or para-position(s) by one, two, three, four or five, especially one or two, halogen atoms and/or OR4 and/or NR5R6 groups and/or alkyl and/or alkenyl and/or alkynyl groups, wherein R4, R5 and R6 each independently of the others have the same meanings as R1, but are independent of R1, or
- R2=a monocyclic 5- or 6-membered heteroaromatic group which may have one or more, especially one or two, O and/or N and/or S atoms in the ring and/or may have OR4 and/or NR5R6 groups and/or alkyl and/or alkenyl and/or alkynyl groups as substituents, wherein R4, R5 and R6 are as defined above. In the definition of R2 there are especially preferred C1-C6-alkyl or C2-C6-alkenyl and -alkynyl groups, especially C1-C4-alkyl or C2-C4-alkenyl and -alkynyl groups. As alkyl groups there are especially preferred methyl, ethyl, propyl and butyl groups and as heteroaromatic groups 6-membered heteroaromatic groups,
- Hal=a halogen atom, such as Br or I,
- X-Y=a group of the formula —CH2CH—OP or —CH═CH—, and
- P=a protecting group, such as TMS.
- The compounds according to the invention may be produced as follows:
-
- as described in DE 195 42 986, the radicals being as defined above. In that reaction, especially the following conditions (i), (iii) and optionally (after (i)) also (ii) may be used:
- (i)
- (a) O3 in a solvent, such as CH2Cl2, and
- (b) reductive working-up, for example with Me2S;
- (ii)
- (a) (CH3CO)2O, HCO2H, NEt3, DMAP;
- (b) DBU; and
- (c) MeOH, NH3; and
- (iii) Me3SiCl, NEt3.
- Compounds of the formula (3) are obtainable by reacting a compound of the formula (2) with a compound of the formula HC[B(OR)2]3, such as tris(ethylenedioxyboryl)methane; R may be an alkyl or alkenyl group as defined above.
- In the reaction there is optionally used a strong base, such as a C1-C4-alkyl-Li compound (such as butyllithium) or a di-C1-C4-alkylamine-Li compound (such as a dimethylamine-lithium compound). The reaction is generally carried out at low temperatures, such as, for example, at temperatures of less than −30° C., preferably at temperatures of less than −50° C., especially preferably at temperatures of at least −78° C. Further reaction conditions may be found in D. Schummer, G. Höfle in Tetrahedron 1995, 51, 11219.
- For example, a compound of the formula (2) is reacted with tris(ethylenedioxyboryl)methane and butyllithium at −78° C. to form a compound of the formula (3).
- A compound of the formula (4) may be produced from a compound of the formula (3) by reaction with N-iodo- or N-bromo-succinimide, optionally in a polar solvent, such as acetonitrile. Further reaction conditions may be found in the following literature reference: N. A. Petasis, I. A. Zavialor,Tetrahedron Lett. 1996, 37, 567.
-
- wherein A1 represents O, S, N or C atoms and the substituents O—, N— and C— correspond to the above-described groups OR4, NR5R6 and alkyl, alkenyl and/or alkynyl groups.
- Especially preferred as substituents “C” are C1-C6-alkyl or C2-C6-alkenyl and/or -alkynyl groups, especially C1-C4-alkyl or C2-C4-alkenyl and/or -alkynyl groups. As alkyl groups there are especially preferred methyl, ethyl, propyl and butyl groups.
-
- wherein the radicals and substituents are as defined above.
- Furthermore, according to the invention, a compound of the formula (6) may be produced by removing the protecting group from the compound of the formula (5), for example with a weak acid, such as citric acid, or compounds such as TBAF, pyridine×HF. Optionally an alcohol, such as methanol, may be used as solvent, the temperature preferably being adjusted to values of, for example, from 40 to 60° C., preferably about 50° C.
- In summary, the compound of the formula (6) may be produced by the above-described steps (epothilon A or B→(2)→(3)→(4)→(5)→(6) or epothilon A or B→(2)→(3)→(5)→(6)).
- According to the invention there are also disclosed medicaments that contain at least one of the compounds (2), (3), (4), (5) or (6) and optionally customary carriers, diluents and adjuvants.
- Such compounds may especially be used also as cytostatic agents and for plant protection in agriculture and/or forestry and/or in horticulture, the compounds optionally being used together with one or more customary carriers, adjuvants and/or diluents.
- Synthesis of the Ketone Derivatives 2
- For a detailed description see DE 195 42 986 A1.
- Synthesis of the Alkenylboronic Acid Derivatives 3
- (see also D. Schummer, G. Höfle,Tetrahedron 1995, 51, 11219)
- Typical Example (R1=H, X-Y=CH2CHOTMS):
- A solution of tris(ethylenedioxyboryl)methane (0.30 g, 1.5 mmol) in CH2Cl2/THF (1:1; 4 ml) was prepared and cooled under inert gas to −78° C. At that temperature, butyllithium (1.6M solution in hexane; 0.73 ml, 1.2 mmol) was added drop-wise in the course of 10 minutes. After 2 hours, ketone 2 (81 mg, 0.15 mmol) in CH2Cl2/THF (1:1, 2 ml) was added, heated to room temperature and stirred for 17 hours. After the addition of MeOH (2 ml), the clear reaction solution was purified by means of preparative HPLC (Lichroprep RP-18, CH3CN/H2O 75:25). 57 mg (65%) of alkenylboronic acid 3 were obtained in the form of an E/Z-isomeric mixture (6:4).
- Selected typical data: LC-MS (ESI-MS): 585 (M++H); 1H-NMR: (300 MHz, CD3OD): E-isomer: 1.91 (S, 3H), 5.16 (d, 1H, 10 Hz), 5.49 (s, 1H), Z-isomer; 1.85 (d, 3H, 1.1 Hz), 4.93 (s, 1H), 5.26 (d, 1H, 9.6 Hz).
- Synthesis of the Iodovinyl Derivatives 4
- (see also N. A. Petasis, I. A. Zavialor,Tetrahedron Lett. 1996, 37, 567)
- Typical Example (R1=H, X-Y=CH2CHOTMS):
- At room temperature, N-iodosuccinimide (6.0 mg, 27 μmol) was added under inert gas and with the exclusion of light to a solution of alkenylboronic acid 3 (12 mg, 21 μmol; E/Z 9:1) in CH3CN (150 μl) and stirred for 3 hours. After concentration, the residue was purified by means of preparative thin-layer chromatography (SiO2, CH2Cl2/MeOH 95:5). 9 mg (66%) of the iodovinyl derivative 4 were isolated in the form of an E/Z-isomeric mixture (9:1).
- Selected typical data: LC-MS (ESI-MS): 667 (M++H); 1H-NMR: (300 MHz, CDCl3); E-isomer: 1.82 (d, 3H, 1.1 Hz), 5.36 (d, 1H, 11 Hz), 6.43 (s, 1H), Z-isomer: 1.84 (d, 3H, 1.1 Hz), 5.54 (d, 1H, 10.5 Hz), 6.09 (s, 1H).
- Suzuki Coupling of the Alkenylboronic Acid 3
- (see also A. Suzuki,Acc. Chem. Res. 1982, 15, 178; A. Torrado, S. Lopez, R. Alvarez, A. R. De Lera Synthesis, 1995, 285)
- Typical Example (R1=H, X-Y=CH2CHOTMS, R2=Ph):
- A solution of alkenylboronic acid 3 (12 mg, 21 μmol; E/Z 2:8) and thallium ethanolate (2M solution in EtOH; 12 μl, 24 μmol) in THF (150 μl) was stirred at room temperature for 15 minutes, then a solution of phenyl iodide (4.0 μl, 6.0 mg, 29 μmol) and tetrakis(triphenylphosphino)-palladium (7.1 mg, 6.2 μmol) in THF (150 μl) was added drop-wise in 30 minutes and again stirred for 30 minutes. After purification by means of preparative thin-layer chromatography (SiO2, CH2Cl2/Et2O 95:5) the phenyl-analogous epothilon 5 (10 mg, 79%, E/Z 2:8) was obtained in the form of a colourless solid.
- Selected typical data: LC-MS (ESI-MS): 617 (M++H); 1H-NMR: (300 MHz, CDCl3): E-isomer: 1.87 (d, 3H, 1.4 Hz), 5.35 (d, 1H, 10.7 Hz), 6.54 (s, 1H), Z-isomer: 1.80 (d, 3H, 1.5 Hz), 5.61 (d, 1H, 10.2 Hz), 6.41 (s, 1H).
- Stille Coupling of the Iodovinyl Derivatives 4
- (see also K. C. Nicolaou, Y. He, F. Roschangar, N. P. King, D. Vourloumis, T. LiAngew. Chem. 1998, 110, (1/2), 89)
Claims (14)
1-17. (cancelled)
19. The compound of claim 18 wherein at least one R is a C1- to C6-alkyl group.
20. The compound of claim 18 wherein at least one R is a C1- to C4-alkyl group.
21. The compound of claim 18 wherein at least one R is a C2- to C6-alkenyl group.
22. The compound of claim 18 wherein at least one R is a C2- to C4-alkenyl group.
23. The compound of claim 18 wherein R1 is a H atom or a C1- to C6-alkyl group.
24. The compound of claim 18 wherein R1 is a H atom or a methyl group.
25. A process for preparing a compound of the formula
wherein
R1 is a H atom or a C1- to C8-alkyl group,
X-Y is a group of the formula —CH2CH(OP)— or —CH═CH—,
P is a protecting group, and
each R is independently a C1- to C8-alkyl group or a C2- to C6-alkenyl group;
comprising: reacting a compound of the formula 2:
with a compound of the formula HC[B(OR)2]3.
26. The process according to claim 25 wherein the compound of the formula HC[B(OR)2]3 is tris(ethylenedioxyboryl)methane.
27. The process according to claim 25 wherein the compound of the formula 2 and the compound of the formula HC[B(OR)2]3 are reacted in the presence of a strong base.
28. The process according to claim 27 wherein the strong base is a C1-C4-alkyl lithium compound or a di-C1-C4-alkylamine lithium compound.
29. The process according to claim 28 wherein the strong base is butyllithium or dimethylamine lithium compound.
30. The process according to claim 25 wherein the compound of the formula II and the compound of the formula HC[B(OR)2]3 are reacted at a temperature of less than about −30° C.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/780,181 US20040259922A1 (en) | 1998-05-08 | 2004-02-17 | Epothilone derivatives, a process for their production thereof and their use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19820599.6 | 1998-05-08 | ||
DE19820599A DE19820599A1 (en) | 1998-05-08 | 1998-05-08 | New epothilone derivatives useful as pharmaceuticals and in plant protection |
US09/674,877 US6982280B1 (en) | 1998-05-08 | 1999-05-07 | Epothilone derivatives, a method for the production thereof, and their use |
US10/780,181 US20040259922A1 (en) | 1998-05-08 | 2004-02-17 | Epothilone derivatives, a process for their production thereof and their use |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/674,877 Division US6982280B1 (en) | 1998-05-08 | 1999-05-07 | Epothilone derivatives, a method for the production thereof, and their use |
PCT/EP1999/003159 Division WO1999058534A2 (en) | 1998-05-08 | 1999-05-07 | Epothilone derivatives, a method for the production thereof, and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040259922A1 true US20040259922A1 (en) | 2004-12-23 |
Family
ID=7867085
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/674,877 Expired - Fee Related US6982280B1 (en) | 1998-05-08 | 1999-05-07 | Epothilone derivatives, a method for the production thereof, and their use |
US10/780,181 Abandoned US20040259922A1 (en) | 1998-05-08 | 2004-02-17 | Epothilone derivatives, a process for their production thereof and their use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/674,877 Expired - Fee Related US6982280B1 (en) | 1998-05-08 | 1999-05-07 | Epothilone derivatives, a method for the production thereof, and their use |
Country Status (14)
Country | Link |
---|---|
US (2) | US6982280B1 (en) |
EP (1) | EP1077980B1 (en) |
JP (1) | JP2002514649A (en) |
KR (1) | KR20010052325A (en) |
AR (1) | AR018344A1 (en) |
AT (1) | ATE234842T1 (en) |
AU (1) | AU754212B2 (en) |
CA (1) | CA2330812A1 (en) |
DE (2) | DE19820599A1 (en) |
ES (1) | ES2195577T3 (en) |
HU (1) | HUP0102283A3 (en) |
IL (1) | IL139480A0 (en) |
TW (1) | TW568910B (en) |
WO (1) | WO1999058534A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8008256B2 (en) | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
US8685668B2 (en) | 2005-02-11 | 2014-04-01 | University Of Southern California | Method of expressing proteins with disulfide bridges |
US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
GB9810659D0 (en) | 1998-05-18 | 1998-07-15 | Ciba Geigy Ag | Organic compounds |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6719540B2 (en) | 2002-03-12 | 2004-04-13 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
DE10355223A1 (en) | 2003-11-26 | 2005-06-30 | Institut für Pflanzenbiochemie (IPB) | New macrocycles for the treatment of cancer |
EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
JP2009532035A (en) | 2006-03-31 | 2009-09-10 | ブリストル−マイヤーズ スクイブ カンパニー | Biomarkers and methods for determining sensitivity to microtubule stabilizers |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
DE102007059752A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Functionalized solid polymer nanoparticles containing epothilones |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
WO2013092983A2 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6744212B2 (en) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Enzymatic binding of polypeptides |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5351146A (en) * | 1993-03-01 | 1994-09-27 | At&T Bell Laboratories | All-optical network architecture |
US5781537A (en) * | 1995-07-07 | 1998-07-14 | International Business Machines Corporation | Setting up, taking down and maintaining connections in a communications network |
US6304349B1 (en) * | 1998-06-30 | 2001-10-16 | Lucent Technologies Inc. | WDM optical communications networks and methods for provisioning |
US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US20020097671A1 (en) * | 2000-12-21 | 2002-07-25 | At&T Corp. | Method for selecting a restoration path in a mesh network |
US6445844B1 (en) * | 1999-09-15 | 2002-09-03 | Xros, Inc. | Flexible, modular, compact fiber optic switch |
US20020126343A1 (en) * | 2000-11-14 | 2002-09-12 | Andrea Fumagalli | System and method for configuring optical circuits |
US20020154357A1 (en) * | 2001-03-29 | 2002-10-24 | Cuneyt Ozveren | Methods and apparatus for reconfigurable WDM lightpath rings |
US20020194339A1 (en) * | 2001-05-16 | 2002-12-19 | Lin Philip J. | Method and apparatus for allocating working and protection bandwidth in a telecommunications mesh network |
US20020196808A1 (en) * | 2001-02-21 | 2002-12-26 | Ramesh Karri | Signaling for reserving a communications path |
US20030009582A1 (en) * | 2001-06-27 | 2003-01-09 | Chunming Qiao | Distributed information management schemes for dynamic allocation and de-allocation of bandwidth |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4138042C2 (en) * | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilones, their production processes and agents containing these compounds |
ES2206607T3 (en) | 1995-11-17 | 2004-05-16 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | DERIVATIVES OF EPOTILONES, PREPARATION AND USE. |
DE19542986A1 (en) * | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | New epothilone derivatives useful as cytostatics |
DE59712968D1 (en) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilones E and F |
-
1998
- 1998-05-08 DE DE19820599A patent/DE19820599A1/en not_active Withdrawn
-
1999
- 1999-05-07 US US09/674,877 patent/US6982280B1/en not_active Expired - Fee Related
- 1999-05-07 AU AU43611/99A patent/AU754212B2/en not_active Ceased
- 1999-05-07 CA CA002330812A patent/CA2330812A1/en not_active Abandoned
- 1999-05-07 DE DE59904632T patent/DE59904632D1/en not_active Expired - Lifetime
- 1999-05-07 HU HU0102283A patent/HUP0102283A3/en unknown
- 1999-05-07 WO PCT/EP1999/003159 patent/WO1999058534A2/en not_active Application Discontinuation
- 1999-05-07 JP JP2000548338A patent/JP2002514649A/en not_active Withdrawn
- 1999-05-07 AT AT99926300T patent/ATE234842T1/en not_active IP Right Cessation
- 1999-05-07 KR KR1020007012437A patent/KR20010052325A/en not_active Application Discontinuation
- 1999-05-07 ES ES99926300T patent/ES2195577T3/en not_active Expired - Lifetime
- 1999-05-07 EP EP99926300A patent/EP1077980B1/en not_active Expired - Lifetime
- 1999-05-07 IL IL13948099A patent/IL139480A0/en unknown
- 1999-05-10 AR ARP990102186A patent/AR018344A1/en not_active Application Discontinuation
- 1999-05-14 TW TW088107412A patent/TW568910B/en not_active IP Right Cessation
-
2004
- 2004-02-17 US US10/780,181 patent/US20040259922A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5351146A (en) * | 1993-03-01 | 1994-09-27 | At&T Bell Laboratories | All-optical network architecture |
US5781537A (en) * | 1995-07-07 | 1998-07-14 | International Business Machines Corporation | Setting up, taking down and maintaining connections in a communications network |
US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6304349B1 (en) * | 1998-06-30 | 2001-10-16 | Lucent Technologies Inc. | WDM optical communications networks and methods for provisioning |
US6445844B1 (en) * | 1999-09-15 | 2002-09-03 | Xros, Inc. | Flexible, modular, compact fiber optic switch |
US20020126343A1 (en) * | 2000-11-14 | 2002-09-12 | Andrea Fumagalli | System and method for configuring optical circuits |
US20020097671A1 (en) * | 2000-12-21 | 2002-07-25 | At&T Corp. | Method for selecting a restoration path in a mesh network |
US20020196808A1 (en) * | 2001-02-21 | 2002-12-26 | Ramesh Karri | Signaling for reserving a communications path |
US20020154357A1 (en) * | 2001-03-29 | 2002-10-24 | Cuneyt Ozveren | Methods and apparatus for reconfigurable WDM lightpath rings |
US20020194339A1 (en) * | 2001-05-16 | 2002-12-19 | Lin Philip J. | Method and apparatus for allocating working and protection bandwidth in a telecommunications mesh network |
US20030009582A1 (en) * | 2001-06-27 | 2003-01-09 | Chunming Qiao | Distributed information management schemes for dynamic allocation and de-allocation of bandwidth |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8685668B2 (en) | 2005-02-11 | 2014-04-01 | University Of Southern California | Method of expressing proteins with disulfide bridges |
US8008256B2 (en) | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
Also Published As
Publication number | Publication date |
---|---|
EP1077980B1 (en) | 2003-03-19 |
ES2195577T3 (en) | 2003-12-01 |
DE19820599A1 (en) | 1999-11-11 |
DE59904632D1 (en) | 2003-04-24 |
KR20010052325A (en) | 2001-06-25 |
AU754212B2 (en) | 2002-11-07 |
JP2002514649A (en) | 2002-05-21 |
IL139480A0 (en) | 2001-11-25 |
AU4361199A (en) | 1999-11-29 |
WO1999058534A3 (en) | 2000-01-13 |
CA2330812A1 (en) | 1999-11-18 |
WO1999058534A2 (en) | 1999-11-18 |
EP1077980A2 (en) | 2001-02-28 |
HUP0102283A3 (en) | 2002-03-28 |
HUP0102283A2 (en) | 2001-10-28 |
US6982280B1 (en) | 2006-01-03 |
ATE234842T1 (en) | 2003-04-15 |
AR018344A1 (en) | 2001-11-14 |
TW568910B (en) | 2004-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040259922A1 (en) | Epothilone derivatives, a process for their production thereof and their use | |
MXPA06000951A (en) | Regioselective synthesis of cci-779. | |
KR102621941B1 (en) | Method for the synthesis of rapamycin derivatives | |
HU203555B (en) | Process for producing glycero-phospho-colin- and glycero-phospho-etanol-amine derivatives | |
US6008363A (en) | Process for producing guanidine derivatives, intermediates therefor and their production | |
KR101728443B1 (en) | Method for Producing Benzyl Ester 2-aminonicotinicotinate Derivative | |
CN110950836B (en) | Preparation method of benzodithiol heterocyclic alkene skeleton compound | |
Reddy et al. | Chemo‐and regioselective allylic oxidation: Oxo‐derivatives of 2‐phospholene sugar analogs | |
CN105037428A (en) | Preparation method for coumarin-3-phosphonate derivative | |
US4927943A (en) | Substituted 7-oxomitosanes | |
JP5270549B2 (en) | Method for producing HI-6 dimethanesulfonate | |
US5654429A (en) | Method for the preparation of 3-amino-2-chloro-4-alkylpyridines | |
KR0145402B1 (en) | Process for preparing of (+)2-benzoyl-3-c silyloxyprop-2(s)-yl) aminoacrylatederivatives | |
US5233045A (en) | Process for the preparation of imidazothiazolone derivatives | |
CA2508341A1 (en) | Processes for preparing quinolonecarboxylate derivatives | |
Bradbury et al. | Synthesis of analogs of prostacyclin containing a thiazone ring | |
SE411120B (en) | PROCEDURE FOR THE PREPARATION OF 2-HYDRAZINOBENSOTIAZOLES BY OMAMINATION | |
JP4016098B2 (en) | Novel 1,3-selenazoline derivative and method for producing the same | |
KR20080047315A (en) | Process for producing tricyclic ketone | |
CS235986B2 (en) | Method of 1,1-dioxopenicilanoyloxy-methyl-6-beta-amino- penicilanate production | |
JP2023023286A (en) | Method for manufacturing silafluorene derivative | |
KR100449310B1 (en) | preparation method of 2-deoxy-L-ribose | |
US5097036A (en) | Substituted 7-oxomitosanes | |
KR20220033267A (en) | Method of manufacturing alkyl-D-alaninate | |
MXPA00010953A (en) | Epothilone derivatives, a method for the production thereof, and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |